LQDA
Liquidia Corporation · Healthcare · Medical - Pharmaceuticals
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow +23.9% ·
net new positions +20.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 100 | +24 | 36.67M | $2.92B | +27 | −3 |
| Q1 2026 | 79 | -1 | 26.51M | $999.68M | +6 | −8 |
| Q4 2025 | 81 | 0 | 26.44M | $911.45M | +1 | — |
| Q3 2025 | 17 | +1 | 21.94M | $498.92M | +1 | — |
| Q2 2025 | 13 | -2 | 14.83M | $184.82M | — | −2 |
| Q1 2025 | 12 | 0 | 5.71M | $84.24M | — | — |
| Q4 2024 | 12 | +4 | 4.81M | $56.51M | +4 | — |
| Q3 2024 | 7 | -2 | 2.07M | $20.68M | +1 | −3 |
| Q2 2024 | 9 | — | 2.26M | $27.08M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 1.81M | — | $21.31M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.34M | +8.2% | $15.75M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.34M | +8.2% | $15.75M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 392.56K | +166.2% | $4.62M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Two Sigma Investments ✦ | 381.24K | +21.4% | $4.48M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Marshall Wace ✦ | 286.29K | +92.5% | $3.37M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Marshall Wace ✦ | 286.29K | +92.5% | $3.37M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Marshall Wace ✦ | 286.29K | +92.5% | $3.37M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | Renaissance Technologies ✦ | 228.00K | New | $2.68M | 0.0% | New | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 180.00K | 0.0% | $2.12M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | Wellington Management ✦ | 180.00K | 0.0% | $2.12M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 12 | Adage Capital Partners ✦ | 84.38K | New | $992,262 | 0.0% | New | 1 | SEC ↗ |
| 13 | Millennium Management ✦ | 44.75K | New | $526,295 | 0.0% | New | 1 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 24.62K | +31.8% | $290,000 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 20.46K | -5.2% | $240,645 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 20.46K | -5.2% | $240,645 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | D. E. Shaw & Co. ✦ | 12.10K | New | $142,261 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Renaissance Technologies | $2.68M | 0.0% |
| Adage Capital Partners | $992,262 | 0.0% |
| Millennium Management | $526,295 | 0.0% |
| D. E. Shaw & Co. | $142,261 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 242 holders, 61.34M shares, $2.26B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 41.83K sh · $2.89M
Officer · 31.80K sh · $2.20M
Director · 18.39K sh · $1.33M
Director · 36.79K sh · $2.76M
Officer · 50.00K sh · $3.70M
Officer · 29.53K sh · $2.27M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology